Article Text

PDF
Greater reduction of knee than hip pain in osteoarthritis treated with naproxen, as evaluated by WOMAC and SF-36
  1. O Svensson1,
  2. M Malmenäs1,
  3. L Fajutrao1,
  4. E M Roos2,
  5. L S Lohmander2
  1. 1AstraZeneca R&D, Södertälje, Sweden
  2. 2Lund University, Clinical Sciences Lund, Department of Orthopaedics, Lund, Sweden
  1. Correspondence to:
    Professor Stefan Lohmander
    Lund University, Clinical Sciences Lund, Department of Orthopaedics, Lund University Hospital, SE-22185 Lund, Sweden; stefan.lohmander{at}med.lu.se

Abstract

Objectives: To compare the improvement of hip and knee osteoarthritis during treatment with naproxen.

Methods: Men and women aged 40 to 75 years with symptomatic osteoarthritis of the knee or hip of at least three months’ duration participated in a six week placebo controlled, double blind study with naproxen 500 mg twice daily as one treatment arm. Naproxen was given to 403 patients (280 knee, 123 hip) and placebo to 108 patients (75 knee, 33 hip). WOMAC (Western Ontario and McMaster Universities osteoarthritis index) 3.1 visual analogue scale and SF-36 (36 item short form health survey) were used to assess response to treatment between baseline and week 6.

Results: There were no differences at baseline between knee and hip osteoarthritis for any of the WOMAC subscales or SF-36 domains. Improvement was between 4 and 7 mm greater for knee than for hip for all WOMAC subscales (pain, Δ = 4.7 mm (p = 0.03); stiffness, Δ = 6.6 mm (p = 0.004); function, Δ = 4.8 mm (p = 0.06)). Effect size was about 0.8 for all WOMAC subscales for the knee and between 0.5 and 0.6 for the hip. Knee patients treated with naproxen improved 4.6 (p = 0.033) more than hip patients for SF-36 bodily pain and 10.3 (p = 0.014) more for SF-36 role–physical.

Conclusions: Patients with knee osteoarthritis improved more with naproxen treatment than patients with hip osteoarthritis, as monitored by WOMAC and the SF-36 domains bodily pain and role–physical. These findings warrant further investigation and strongly suggest that efficacy of treatment of osteoarthritis of knee and hip should be evaluated separately.

  • SF-36, 36 item short form health survey
  • NSAID, non-steroidal anti-inflammatory drug
  • OARSI, OsteoArthritis Research Society International
  • OMERACT, Outcome Measures in Arthritis Clinical Trials
  • VAS, visual analogue scale
  • WOMAC, Western Ontario and McMaster Universities osteoarthritis index
  • WOMAC
  • SF-36
  • osteoarthritis
  • naproxen

Statistics from Altmetric.com

Footnotes

  • Published Online First 3 November 2005

  • OS, MM, and LF are employees of AstraZeneca R&D, Sweden. EMR and LSL have declared no conflict of interest in relation to the subject matter of this report.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.